QuidelOrtho Launches New Rapid Flu & COVID-19 Test
Table of Contents
QuidelOrtho (QDEL) recently announced the release of the QUICKVUE Influenza + SARS Test, a rapid, CLIA-waived diagnostic solution. This test allows healthcare professionals too quickly differentiate between influenza A, influenza B, and COVID-19 using a single swab. This offers faster results and potentially improved treatment decisions for clinics, urgent care centers, and hospital labs, especially as cold and flu season approaches.
Key Features of the QUICKVUE Influenza + SARS Test
- Rapid Results: Provides quick diagnosis for timely treatment.
- CLIA-Waived: Simplifies testing in various healthcare settings.
- Multiplex Testing: Detects Flu A, Flu B, and COVID-19 from a single sample.
QuidelOrtho’s Recent Performance
Despite continuous innovation, QuidelOrtho’s stock has faced challenges over the past year. While annual revenue has increased, net income remains negative, and the stock has declined by nearly 38% in the last year. The diagnostics industry is navigating shifting testing demands and funding constraints, even with advancements in products like the newly launched test. Recent financial reports haven’t demonstrated consistent positive momentum, although the company’s value score suggests potential hidden value.
will the New Test Drive a Rebound?
The question now is whether this new product launch can act as a catalyst for a stock rebound, or if the market has already factored in QuidelOrtho’s future growth expectations. The QUICKVUE Influenza + SARS Test integrates seamlessly into the existing QUICKVUE product line and reinforces QuidelOrtho’s commitment to leading the respiratory diagnostics market.
Investor Sentiment: Undervaluation
The most prevalent investor narrative suggests QuidelOrtho is currently undervalued compared to its estimated fair value. This reflects optimism regarding the company’s potential for recovery and future growth.
Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China, where differentiated technology, low market share, and a large runway for immunoassay growth exist, positions QuidelOrtho for significant future expansion.
Key Takeaways
- quidelortho’s new test offers a rapid and convenient solution for diagnosing influenza and COVID-19.
- The company has faced financial headwinds despite ongoing innovation.
- Investor sentiment leans towards undervaluation,suggesting potential for growth.
Publication Date: 2025/09/27 22:56:25